Rimonabant: obituary for a wonder drug

  title={Rimonabant: obituary for a wonder drug},
  author={S. Matthijs Boekholdt and Ron J. G. Peters},
  journal={The Lancet},
Abdominal obesity leads to a range of cardiovascular risk factors, including insulin resistance or overt diabetes, hypertension, hypertriglyceridaemia, and low HDL cholesterol. In theory, interventions to reverse this process should be simple: regular physical activity and a healthier diet. In practice, however, these targets are rarely achieved. A drug that could help to reduce weight and reverse these metabolic risk factors is eagerly awaited. Rimonabant is a selective blocker of the… CONTINUE READING


Publications citing this paper.
Showing 1-8 of 8 extracted citations


Publications referenced by this paper.
Showing 1-7 of 7 references

Eff ects of the cannabinoid - 1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients : 1 - year experience from the RIO - Europe study

  • LF VanGaal, AM Rissanen, AJ Scheen, O Ziegler, S Rossner
  • Lancet
  • 2005

European Medicines Agency recommends suspension of the marketing authorisations for sibutramine . Jan 21 , 2010

  • JA Iestra, D Kromhout, YT vanderSchouw, DE Grobbee, HC Boshuizen, WA vanStaveren

Similar Papers

Loading similar papers…